AVN-211

AVN-211
Identifiers
	IUPAC name 5,7-Dimethyl-2-(methylsulfanyl)-3-(phenylsulfonyl)pyrazolo[1,5-a]pyrimidine;
ChemSpider	26387125;
ChEMBL	CHEMBL1668500;
Chemical and physical data
Formula	C15H15N3O2S2
Molar mass	333.42 g·mol−1
3D model (Jmol)	Interactive image;
	SMILES Cc1cc(n2c(n1)c(c(n2)SC)S(=O)(=O)c3ccccc3)C ;
	InChI InChI=1S/C15H15N3O2S2/c1-10-9-11(2)18-14(16-10)13(15(17-18)21-3)22(19,20)12-7-5-4-6-8-12/h4-9H,1-3H3 ; Key:KSAUCBGUWGWPDL-UHFFFAOYSA-N ;

AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT₆ receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia.^[1]^[2]^[3] In early 2011, it successfully completed phase IIa clinical trials,^[1]^[4] with benefits on positive symptoms and some procognitive effects observed,^[5] and in mid 2013, phase IIb clinical trials for schizophrenia began.^[6] Avineuro Pharmaceuticals has also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease in 2015.^[6]^[7]

References[edit]

^ ^a ^b Sylvain Celanire; Sonia Poli (13 October 2014). Small Molecule Therapeutics for Schizophrenia. Springer. pp. 31, 37. ISBN 978-3-319-11502-3.
^ Pharmacology of 5-HT6 receptors. Academic Press. 7 December 2010. pp. 164–. ISBN 978-0-12-384977-9.
^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.
^ http://www.avineuro.com/avineuro-pharmaceuticals-inc-reports-positive-phase-2a-clinical-proof-of-concept-trial-results-on-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/
^ Morozova, Margarita A.; Lepilkina, Taisiya A.; Rupchev, Georgy E.; Beniashvily, Allan G.; Burminskiy, Denis S.; Potanin, Sergey S.; Bondarenko, Evgeny V.; Kazey, Vasily I.; Lavrovsky, Yan; Ivachtchenko, Alexandre V. (2013). "Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study". CNS Spectrums. 19 (04): 316–323. doi:10.1017/S1092852913000394. ISSN 1092-8529.
^ ^a ^b http://www.avineuro.com/avineuro-pharmaceuticals-inc-announces-beginning-of-phase-2b-clinical-studies-of-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/
^ Ivachtchenko AV, Lavrovsky Y, Ivanenkov YA (2016): "AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer’s Disease", Molecular Pharmaceutics, 13 (3), 945–963. PMID 26886442

External links[edit]

Pipeline - Avineuro Pharmaceuticals, Inc.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[CelanirePoli2014-1] Sylvain Celanire; Sonia Poli (13 October 2014). Small Molecule Therapeutics for Schizophrenia. Springer. pp. 31, 37. ISBN 978-3-319-11502-3.

[2] Pharmacology of 5-HT6 receptors. Academic Press. 7 December 2010. pp. 164–. ISBN 978-0-12-384977-9.

[3] "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.

[Avineuro2011-4] ttp://www.avineuro.com/avineuro-pharmaceuticals-inc-reports-positive-phase-2a-clinical-proof-of-concept-trial-results-on-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/

[MorozovaLepilkina2013-5] Morozova, Margarita A.; Lepilkina, Taisiya A.; Rupchev, Georgy E.; Beniashvily, Allan G.; Burminskiy, Denis S.; Potanin, Sergey S.; Bondarenko, Evgeny V.; Kazey, Vasily I.; Lavrovsky, Yan; Ivachtchenko, Alexandre V. (2013). "Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study". CNS Spectrums. 19 (04): 316–323. doi:10.1017/S1092852913000394. ISSN 1092-8529.

[Avineuro2013-6] ttp://www.avineuro.com/avineuro-pharmaceuticals-inc-announces-beginning-of-phase-2b-clinical-studies-of-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/

[7] Ivachtchenko AV, Lavrovsky Y, Ivanenkov YA (2016): "AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer’s Disease", Molecular Pharmaceutics, 13 (3), 945–963. PMID 26886442

[1]

[2]

[3]

[4]

[5]

[6]

[7]

v t e Antipsychotics (neuroleptics) (N05A)

Typical	Benzamides Levosulpiride Sulpiride Veralipride^‡ Butyrophenones Azaperone Benperidol Bromperidol Droperidol Fluanisone Haloperidol^# Lenperone Moperone Pipamperone Spiperone Timiperone Trifluperidol Diphenylbutylpiperidines Clopimozide Fluspirilene Penfluridol Pimozide Phenothiazines Acepromazine Acetophenazine Butaperazine Carphenazine (carfenazine) Chloracizine Chlorproethazine Chlorpromazine Cyamemazine Dixyrazine Fluacizine Fluphenazine Levomepromazine/Methotrimeprazine Mesoridazine Perazine Periciazine Perphenazine Perphenazine 4-aminobutyrate Piperacetazine Pipotiazine Prochlorperazine Promazine Promethazine Sulforidazine Thiethylperazine Thiopropazate Thioproperazine Thioridazine Trifluoperazine Triflupromazine Thioxanthenes Chlorprothixene Clopenthixol Clothixamide Flupentixol Fluprothixene Piflutixol Teflutixol Thiothixene Zuclopenthixol Tricyclics Fluotracen Loxapine Trimipramine Others Butaclamol Prothipendyl

Atypical	Benzamides Amisulpride Nemonapride Remoxipride^‡ Sultopride Tiapride Butyrophenones Cinuperone Melperone Setoperone Benzo(iso)oxazole piperidines Iloperidone Ocaperidone^§ Paliperidone Risperidone^# Benzo(iso)thiazole piperazines Lurasidone Perospirone Revospirone^§ Tiospirone^§ Ziprasidone Diphenylbutylpiperazines Amperozide Phenylpiperazines Aripiprazole Aripiprazole lauroxil Bifeprunox^§ Brexpiprazole Cariprazine Tricyclics Amoxapine Asenapine Carpipramine Clocapramine Clorotepine Clotiapine Clozapine^# Flumezapine Fluperlapine Gevotroline Metitepine Mosapramine Olanzapine Quetiapine Tenilapine Zotepine Others Blonanserin Lumateperone^† Molindone Pimavanserin RP5063^† Sertindole Zicronapine^§

Others	Azacyclonol Cannabidiol Oxypertine Reserpine Tetrabenazine

^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

AVN-211

See also[edit]

References[edit]

External links[edit]

Navigation menu

Personal tools

Namespaces

Variants

Views

More

Search

Navigation

Interaction

Tools

Print/export

Languages

Identifiers

IUPAC name 5,7-Dimethyl-2-(methylsulfanyl)-3-(phenylsulfonyl)pyrazolo[1,5-a]pyrimidine
ChemSpider	26387125
ChEMBL	CHEMBL1668500
Chemical and physical data
Formula	C₁₅H₁₅N₃O₂S₂
Molar mass	333.42 g·mol⁻¹
3D model (Jmol)	Interactive image
SMILES Cc1cc(n2c(n1)c(c(n2)SC)S(=O)(=O)c3ccccc3)C
InChI InChI=1S/C15H15N3O2S2/c1-10-9-11(2)18-14(16-10)13(15(17-18)21-3)22(19,20)12-7-5-4-6-8-12/h4-9H,1-3H3 Key:KSAUCBGUWGWPDL-UHFFFAOYSA-N